• EchoSolv AS deployed into leading US health system Mount Sinai Health System
• Mount Sinai Health System comprises seven hospitals, over 400 outpatient practices, and +3,760 beds
• Mount Sinai Fuster Heart Hospital ranked No. 1 in New York and No. 2 in the nation for Cardiology, Heart & Vascular Surgery

Echo IQ Limited (ASX: EIQ) is pleased to announce that it has deployed its AI-based decision support software for the assessment of severe aortic stenosis, EchoSolv AS, with Mount Sinai Health System in New York, USA. Mount Sinai Health System comprises seven hospitals, more than 400 outpatient practices, and a globally recognised medical school, the Icahn School of Medicine at Mount Sinai. Specifically, Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 1 in New York and No. 2 in the nation for Cardiology, Heart & Vascular Surgery. The system services millions of patient interactions annually, encompasses over 3,760 beds across campuses, and is consistently ranked among the top hospitals in the US across multiple specialties, including cardiology and heart surgery. The deployment marks a significant milestone for Echo IQ and reflects the Company's continued growth as health systems and cardiology practices seek practical AI products that can be integrated into existing clinical workflows. Collaboration with a leading medical system such as Mount Sinai Health System also supports the Company's stated strategy of expanding EchoSolv AS adoption at prominent cardiovascular institutions. Echo IQ views the deployment as an important milestone in not only building commercial traction but also providing future research opportunities as the Company pursues new product development opportunities.

The Company continues to engage with prospective US healthcare providers regarding potential EchoSolv AS opportunities and will provide updates as appropriate.